Pharnext SA develops and manufactures drugs for neurological diseases. Its products include R&D Pipeline, PXT3003, and PXT864 are used for the treatment of Charcot-Marie-Tooth disease, diabetic, and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 by Daniel Cohen, Loic Heidsieck, Serguei Nabirotchkine, Oxana Guerassimenko and Ilya Chumakov and is headquartered in Paris, France.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is the 52-week high for Pharnext?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Pharnext 52 week high is $25,000.00 as of September 06, 2025.
What is the 52-week low for Pharnext?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Pharnext 52 week low is $25,000.00 as of September 06, 2025.
What is Pharnext stock price today?
Pharnext stock price today is $25,000.00.
What is the 50-day moving average of Pharnext?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Pharnext 50-day moving average is $25,000.00.